News

Flywire Investors Alert: Key Information for Shareholders

Flywire Investors Alert: Key Information for Shareholders

Attention Flywire Investors

Investors in Flywire Corporation, particularly those who suffered significant financial losses, should be aware of an important class action lawsuit. If you have incurred losses exceeding $100,000, there is a vital deadline approaching to file your applications as lead plaintiffs. The firm handling this case, Kahn Swick & Foti, LLC, is urging affected investors to take timely action.

Understanding Your Rights

To qualify as a lead plaintiff, you must act swiftly and file your application by the stated deadline. The class period for this lawsuit spans from February 28, 2024, to February 25, 2025. This timeframe is critical for potential plaintiffs as it outlines the period in which financial losses are attributed to the company's alleged omissions and misrepresentations.

What is a Class Action Lawsuit?

A class action lawsuit allows a group of individuals with similar claims against a defendant to consolidate their cases into a single lawsuit. This is particularly beneficial in securities cases where individual losses may not warrant separate legal action. It also offers collective bargaining power in negotiations and settlements.

Recent Developments at Flywire

Flywire Corporation, listed under the ticker symbol FLYW, has faced scrutiny following its recent financial disclosures. The company's announcement of its fourth-quarter and full-year results for 2024 revealed a loss of $0.12 per share, which fell short of market expectations. Alongside disappointing revenue numbers totaling $117.6 million, the company also indicated a need to reassess its business strategies due to adverse market conditions.

Further complicating matters, Flywire projected a restructuring that would affect approximately 10% of its workforce, hinting at broader operational challenges. The immediate market reaction was swift; on February 26, 2025, Flywire's stock plummeted by 37.36%, underscoring investor anxiety and sentiment surrounding the company's outlook.

The Legal Landscape

The case, formally titled Hickman v. Flywire Corporation, et al., is currently pending in the United States District Court for the Eastern District of New York. This legal proceeding will explore the allegations against Flywire and its leadership regarding nondisclosures that potentially misled investors during the identified class period.

Next Steps for Investors

Investors impacted by the developments at Flywire are encouraged to reach out to Kahn Swick & Foti, LLC for guidance on navigating the complexities of the lawsuit. This firm specializes in securities litigation and aims to assist investors in reclaiming their losses stemming from corporate misconduct. They provide a no-cost consultation to discuss potential actions that affected investors may pursue.

KSF’s managing partner, Lewis Kahn, is available for inquiries, offering insights into the legal process and helping clients understand their rights and options.

About Kahn Swick & Foti, LLC

As one of the nation's leading boutique securities litigation firms, Kahn Swick & Foti, LLC has built a solid reputation for representing clients in complex legal matters involving corporate governance. The firm's expertise is instrumental in assisting investors against powerful corporate entities. KSF's commitment extends to not just institutional clients but also retail investors who seek recourse in instances of fraudulent corporate activities.

Why Choose KSF?

With offices spread across key locations, including New York, California, and Chicago, Kahn Swick & Foti is well-positioned to serve a diverse clientele. They continuously advocate for investor rights and strive to ensure that corporate accountability is upheld. Their recognition among the top law firms based on settlement values speaks volumes about their effectiveness and dedication.

Frequently Asked Questions

What is the deadline to apply as a lead plaintiff in the Flywire case?

The deadline to file applications as a lead plaintiff is set for September 23, 2025.

How can I determine if I qualify for this lawsuit?

If you purchased Flywire’s securities within the class period and incurred losses exceeding $100,000, you may qualify to participate in the lawsuit.

What are the potential outcomes of a class action lawsuit?

Outcomes may include financial settlements from Flywire to affected investors if the court rules in their favor, or possibly dismissals if claims are found unsubstantiated.

Who can I contact for more information?

Investors are encouraged to contact Kahn Swick & Foti, LLC for more details about the lawsuit and their rights.

What should I do if I want to join the class action?

To join the class action, you need to file a motion with the court before the deadline, including any evidence of your financial loss during the class period.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 92

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 158

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading

Top 5 Most Recently Viewed Articles

Spruce Point's Strong Sell Rating Casts Doubt on Construction Partners

Updated Category News Views 116

Spruce Point's Strong Sell Opinion on Construction Partners Inc Spruce Point Capital Management has recently issued a compelling report regarding Construction Partners Inc (NASDAQ: ROAD), a company recognized for its expertise in infrastructure and road construction. This report voices a strong sell recommendation, reflecting serious concerns over the company's current...

Continue Reading
Celebrating Excellence in Healthcare: Press Ganey's Honorees

Updated Category News Views 344

Celebrating the Executive Human Experience Award Winners Press Ganey, an industry leader dedicated to enhancing healthcare experiences, recently celebrated exceptional achievements in the field. During its annual conference, the Executive Human Experience Awards recognized extraordinary contributions from professionals and organizations that prioritize patient, consumer,...

Continue Reading
Commercial Vehicle Market Growth Driven by Technology Advancements

Updated Category News Views 122

Commercial Vehicle Market Growth and Projections The global commercial vehicle market is on an upward trajectory, with sales expected to reach 3.5 million units by 2025. The anticipated Year-over-Year (YoY) growth of 4.4% from 2024 highlights the increasing demand for medium and heavy commercial vehicles. This trend is being driven by several factors, including...

Continue Reading
Atos Receives Prestigious EcoVadis Platinum Medal Again

Updated Category News Views 195

Let’s not beat around the bush—Atos is doing something right in the sustainability game. They've bagged the EcoVadis Platinum Medal for five years running. Yep, that’s a serious flex in today’s corporate climate where ‘green’ isn’t just a buzzword; it’s almost an obligation if you want to stay relevant. The Metrics Behind Atos's Shine Scoring a...

Continue Reading
Power Metallic Mines Updates Shareholder Meeting Outcomes

Updated Category News Views 157

Power Metallic Mines Reports on AGSM Meeting Outcomes Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) expressed satisfaction with the voting outcomes from its Annual General and Special Meeting ("AGSM") that took place recently. The meeting gathered shareholders to discuss essential business items and elect members to the Board of...

Continue Reading